Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials-Reference-Cited by-同舟云学术

Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials

Published:2019-06-03 Issue:7-8 Volume:15 Page:1980-1985
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Gilca Vladimir¹²,Sauvageau Chantal¹²,Panicker Gitika³,De Serres Gaston¹²,Schiller John⁴,Ouakki Manale¹,Unger Elisabeth R.³

Affiliation:

1. Division of Biological Risks, Quebec Public Health Institute, Quebec, Canada

2. Division of Infectious Disease and Immunity, Laval University Research Hospital Center, Quebec, Canada

3. Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

4. Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, USA

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2019.1605278

Reference30 articles.

1. Merck Frosst Canada ltée. GARDASIL - Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine. Product Monograph. Kirkland: Merck Canada Inc. Feb 2015 p. 62. accessed on February 13, 2019 [En ligne]. Disponible: https://www.merck.ca/static/pdf/GARDASIL-PM_E.pdf

2. Merck Canada Inc. Highlights of prescribing information [On line] [accessed 2019 Feb 13] https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_pi.pdf

3. GlaxoSmithKline. CERVARIX® human papillomavirus vaccine types 16 and 18 (recombinant, AS04 adjuvanted) [On line]; 2008. [accessed 2019 Feb 13] https://ca.gsk.com/media/589880/cervarix.pdf

4. Plotkin SA, Orenstein WA, Offit PA. Vaccines. 6th edn ed. Philadelphia, USA: Saunders Elsevier; 2012. p. 1550.

5. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis;The Lancet Global Health;2023-01

2. An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon;The American Journal of Tropical Medicine and Hygiene;2022-11-14

3. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis;The Lancet Infectious Diseases;2021-11

4. Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals;Contemporary Clinical Trials;2021-06

5. Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule;Vaccine;2021-02